Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Mannheim University Medical Center have now discovered that a certain group of cancer drugs (MEK Inhibitors) activates the cancer-promoting Wnt signalling pathway in colorectal cancer cells. This can lead to the accumulation of tumor cells with stem cell characteristics that are resistant to many…
The rate of bowel cancer – also known as colorectal cancer or CRC – is rising among adults aged 20-49 in Europe, suggests new research. Rates rose most steeply among the youngest age group (20-29 years), and the authors warn that if the trend continues, screening guidelines may need to be reconsidered. Rates tend to be lower among people over 50, but the opposite is true among younger adults…
Dr Georg Ralle, General Secretary of the association ‘Network against Colon Cancer’ since 2012 as well as moderator of the symposium ‘The New Measurement of Oncology’, hosted by the National Centre for Tumour Diseases Heidelberg (NCT), clearly voices his dissatisfaction with the German ‘wait it out mentality’. He sharply criticised the Federal Joint Committee (G-BA) and here also…
Shahid Umar, PhD, researcher with The University of Kansas Cancer Center, has dedicated two decades of his scientific exploration to better grasp the connection between colon cancer and the human microbiome. Called the “forgotten organ,” the microbiome comprises trillions and trillions of microbes, including bacteria, fungi and viruses, in our body.
Current faecal blood tests for colorectal cancer have a sixty percent false positive rate. New funding from Cancer Research UK is helping scientists at Cardiff University to find better, safer tests. Inaccuracy of initial tests for colorectal cancer are putting patients at unnecessary risk, highlighting vital need for the development of precise and non-invasive testing. A grant of over £400,000…
Cell stress in combination with an altered microbiota in the colon drives tumour growth. Previously, it was assumed that this combination only contributes to inflammatory intestinal diseases.
Obesity, cancers and other gastrointestinal diseases have digestive systems all over Europe in a chokehold. In a new report, non-profit organisation United European Gastroenterology (UEG) sheds a spotlight on the issues, challenges and inequalities of digestive health - and points out ways to fix the most pressing problems.
The decline in cancer of the intestines – colorectal cancer – is one of the major success stories of the past 30 years in Europe say researchers, as they predict that in 2018 death rates from the disease will continue to fall by around seven per cent compared to 2012. In a study published in the leading cancer journal Annals of Oncology, researchers predict that death rates in the European…
Although modern medicine has made progress in the fight against cancer, the fear of cancer diseases is widespread. Still, regular screenings are no matter of course. Only almost every fifth person over 55 years has undergone a colonoscopy even though it is recommend for this age group as cancer prevention. What influences people to undergo these screenings? Screening or not? In making this…
New research from the University of California, Los Angeles (UCLA) could help explain the link between a high-cholesterol diet and an elevated risk for colon cancer. In a study of mice, scientists from the David Geffen School of Medicine at UCLA discovered that boosting the animals’ cholesterol levels spurred intestinal stem cells to divide more quickly, enabling tumors to form 100 times…
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer. The test, called CancerSEEK, is a unique noninvasive, multianalyte test that simultaneously evaluates levels of eight cancer proteins and the presence of cancer gene mutations from circulating DNA in the blood. The test is aimed at…
Selective internal radiotherapy (SIRT) is often only looked at from a palliative perspective. However, the procedure is now also increasingly moving into the curative field, as Prof. Dr. Jens Ricke, Chair of Radiology at the Ludwig-Maximilian University Munich and Director of the Clinic and Polyclinic for Radiology at the University Hospital of the LMU reports. “As a locoregionally used…
Early-stage colon cancer patients could benefit in the future from specific genetic tests that forecast their prognosis and help them make the right decision regarding chemotherapy.
Billy Boyle, Founder and CEO of Owlstone Medical, a diagnostics company developing a breathalyzer for disease, is to be awarded the Royal Academy of Engineering’s prestigious Silver Medal. The award recognizes engineer Billy’s work in spearheading the development of the company’s Breath Biopsy platform and driving a vision to save 100,000 lives and $1.5 billion in healthcare costs.
Raising the age limit for routine genetic testing in colorectal cancer could identify more cases of families affected by Lynch syndrome, a condition that accounts for around 5% of all colon cancers, according to new research to be presented at the annual conference of the European Society of Human Genetics.
PENTAX Medical EMEA announces its continued cooperation with SMART Medical to support the distribution and deployment of SMART’s G-EYE technology integrated with PENTAX Medical’s HD+ systems to the EMEA market.
Colon cancer is one of the most common forms of cancer in Germany. Prof. Dr. med. Sebastian Zeißig, group leader at the DFG Research Center for Regenerative Therapies Dresden (CRTD) - Cluster of Excellence at the TU Dresden and physician at the Department of Medicine I, University Hospital Carl Gustav Carus Dresden, has now shown a decisive role of gut bacteria in the regulation of intestinal…
A leading cause of cancer deaths worldwide, colon cancer is famously resistant to treatment. There are many reasons for this, but one has to do with a group of persisting cancer cells in the colon that cause relapses. Conventional therapies against them are mostly ineffective. EPFL scientists have now identified a biological mechanism that can be exploited to counteract colon cancer relapses.
Led by Professor Teoh Swee Hin, scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells. Harvesting the Clostridium sporogenes bacteria found commonly in soil, the NTU team was able to harness the bacteria in its dead form, and its secretions, to destroy colon tumours cells effectively.
Chemists at Caltech have developed a new sensitive technique capable of detecting colorectal cancer in tissue samples—a method that could one day be used in clinical settings for the early diagnosis of colorectal cancer.
Innovative endoscopy system improves adenoma detection. Endoscopes are thin flexible tubes with imaging capabilities that doctors use to view the upper and lower GI tracts of their patients. The Fuse system uses three small cameras at the tip of a flexible GI endoscope, as compared with one at the tip of a standard, forward-viewing endoscope. With a wider 330° view, physicians see nearly twice…
‘Health insurers should keep a tighter rein on the quality of endoscopic interventions because, mostly, they represent a gentler alternative to surgery,’ asserts international expert Horst Neuhaus, during an EH interview. Report: Daniela Zimmermann/Juliane Dannert
Scientists from the Hubrecht Institute and the University Medical Center Utrecht (UMC Utrecht) have developed a cell culture model of human colon cancer progression. This model mimics the situation in patients more closely than any other colon cancer model so far. It enables researchers to study processes involved in colon cancer development and find new cancer drugs.
The number of cancer patients in Germany continues to rise steadily. An increase in the number of newly diagnosed cases of 14% is expected by 2020 compared to 2008. Therefore early detection is increasingly the focus of attention.
Founded in Germany 25 years ago, EKF Diagnostics’ PLC HQ is currently in Cardiff, Wales, where the firm is pursuing the development of a molecular assay for specific cancer types.